Lario Therapeutics are developing first-in-class disease modifying treatments for severe neurological disorders. Precision Neuroscience Today.
Total raised: $6M
Investors 1
| Date | Name | Website |
| - | Epidarex C... | epidarex.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.07.2024 | Grant | $6M | - |
Mentions in press and media 2
| Date | Title | Description |
| 22.07.2024 | Lario Therapeutics Receives $6M Grant From The Michael J. Fox Foundation for Parkinson’s Research | Lario Therapeutics, an Edinburgh, Scotland, UK-based biopharmaceutical company developing precision medicines for epileptic and neurological disorders, received a $6M Grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).... |
| 07.11.2023 | Lario Therapeutics receives “Company Making a Difference Award” from CDLK5 Forum, recognising its unique approach to precision medicine for genetic epilepsies | CDLK5 Forum Award for Excellence - Company Making a Difference 2023 Pre-clinical” presented by the Loulou Foundation at the CDKL5 Forum, 6th-7th November in London First-in-class ion channel inhibitors show promise as anti-seizure therapeut... |